Business
Galectin Therapeutics Discusses Corporate Transformation, Progress of NAVIGATE Trial and Outlines Strategy for Potential Phase 2 Cancer Immunotherapy Trial at Annual Meeting
NAVIGATE clinical trial in NASH cirrhosis now underway in all countries originally selected; full enrollment expected by mid-2022 Dr. Chetan Bettegowda, of
About this update from Galectin Therapeutics Inc.
[{"type":"text","content":"NAVIGATE clinical trial in NASH cirrhosis now underway in all countries originally selected; full enrollment expected by mid-2022 Dr. Chetan Bettegowda, of Johns Hopkins, and Drs. Nishant Agrawal and Ari Rosenberg, both of the University of Chicago Medical Center, engaged to advise on path forward in oncology Cancer immunotherapy efforts likely to focus on Head and Neck cancers Shareholders approved all proposals, including the reelection of its Board of Directors NORCROSS, Ga., Dec. 13, 2021 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectins, provided an update on its strategy and clinical trial progress at its 2021 Annual Meeting, held virtually on December 3, and reported that shareholders approved all proposals, including the reelection of its Board of Directors. “Compared to a year ago, Galectin Therapeutics has been transformed into a new company,” said Joel Lewis, Chief Executive Officer and President of Galectin Therapeutics. “The addition of highly-skilled and experienced professionals to our management team and advisors, most prominently Dr. Ben Carson, continued progress with our global NASH cirrhosis registration trial, and the Board’s authorization to evaluate the initiation of a company-sponsored Phase 2 oncology program, enhances Galectin Therapeutics’ position as the leader in galectin 3 inhibition.” During the Annual Meeting, Mr. Lewis and Dr. Pol Boudes, Chief Medical Officer of Galectin Therapeutics, made a presentation highlighting the following: Update on Oncology Program Recently engaged three noted physicians – Dr. Chetan Bettegowda, from Johns Hopkins, and Dr. Nishant Agrawal and Dr. Ari Rosenberg, both from University of Chicago Medical Center – as consultants to help define the path forward in oncology.Strategic review with Drs. Bettegowda, Argawal and Rosenberg identified Head and Neck cancer patients as the population in highest need of new treatment, and a potential protocol for a Phase 2 trial of belapectin in combination therapy in this indication is under development. Update on NAVIGATE Study in NASH Cirrhosis Despite the challenges presented by COVID-19, particularly outside the U.S., the NAVIGATE Phase 2b/3 trial in NASH cirrhosis has been initiated in all countries originally selected for participation.To balance the risks...